First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study

Breast Cancer Research

Gabriel N Hortobagyi²  Debra Frye²  Moshe Fridman¹  M Haim Erder³  Edgardo Rivera² 

[1] AMF Consulting Inc., Los Angeles, California, USA;University of Texas, MD Anderson Cancer Center, Houston, Texas, USA;Amgen Inc, Thousand Oaks, California, USA

关键词: neutropenia;    myelosuppression;    hospitalization;    filgrastim;    chemotherapy;   

Others  :  1118800
DOI  :  10.1186/bcr618

 received in 2003-03-11, accepted in 2003-06-04,  发布年份 2003

【 摘 要 】

Background

The nadir value of the absolute neutrophil count (ANC) in the first cycle of chemotherapy is an effective predictor of subsequent neutropenic events. This study was designed to validate an earlier published study based on a retrospective data analysis from a prospective randomized clinical trial.

Methods

The original published model was applied to a trial of 143 patients to cross-validate the model. We also tested the specification of the model on our data by using a logistic regression model with several variables, including first-cycle nadir ANC, age, menopausal status, hormone-receptor status, previous radiotherapy, and first-cycle decrease in hemoglobin concentration. Patients received fluorouracil, doxorubicin, and cyclophosphamide every 21 or 28 days for six cycles without hematopoietic support from colony-stimulating factor.

Results

In the cross-validation analysis, the original model successfully classified patients by risk of neutropenic events (C = 0.78). When the model specification was tested, first-cycle nadir ANC was the sole significant (P < 0.0001) predictor of neutropenic events and the model had a good predictive power (C = 0.78). The estimated relative risk of 4.8 did not differ from the risk cited in the original model (P = 0.91). A significantly higher percentage of our patients with a low first-cycle nadir ANC of 0.25 × 10⁹/liter or less experienced febrile neutropenia (30% versus 10%, P = 0.04) and received at least 85% of the planned dose intensity (55% versus 32%, P = 0.05).

Conclusions

The original risk model used to predict neutropenic events was validated by our study. This information can be used to target high-risk patients for prophylactic treatment with filgrastim (recombinant methionyl human granulocyte colony-stimulating factor) in chemotherapy cycles 2 to 6.

【 授权许可】

   
2003 Rivera et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR: First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998, 16:2392-2400.
• [2]Savvides P, Terrin N, Erban J, Selker HR: Development and validation of a patient-specific predictive instrument for the need for dose-reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors. Proc ASCO 2001, 20:244a.
• [3]Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325:164-170.
• [4]de Graaf H, Willemse PH, Bong SB, Piersma H, Tjabbes T, van Veelen H, Coenen JL, deVries EG: Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor pre-menopausal patients with node-positive breast cancer. Oncology 1996, 53:289-294.
• [5]Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C: Recombinant granulocyte colony-stimulating factor reduces the infection complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29A:319-324.
• [6]Link BK, Budd GT, Scott S, Dickman E, Paul D, Lawless G, Lee MW, Fridman M, Ford J, Carter WB, Oncology Practice Pattern Study Working Group: Delivering adjuvant chemotherapy to women with early-stage breast cancer: current patterns of care. Cancer 2001, 92:1354-1367.
• [7]Smith GA, Fine MJ, Lenert LL, Newbold RC: Project ChemoIn-sight reveals physician practice patterns for adjuvant breast cancer chemotherapy, and compares the dose intensity of CMF, AC, and CAF. Proc ASCO 1999, 18:78a.
• [8]Weiss R, Valagussa P, Moliterni A, Zambetti M, Buzzoni R, Bonadonna G: Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy. Analysis of drug dosing and toxicity. Am J Med 1987, 83:455-463.
• [9]Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Mus HB, Green MR, Norton L, Frei E: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998, 90:1205-1211.
• [10]Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995, 332:901-906.
• [11]Silber JH, Fridman M, Shpilsky A, Even-Shoshan O, Smink DS, Jayaraman J, Fox KR, Pauly MV: Modeling the cost effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998, 16:2435-2444.
• [12]Rosner B: Fundamentals of Biostatistics. 5th edition. Boston: PWS-Kent Publishing Company; 2000:63-65.
• [13]Hosmer DW, Lemeshow S: Applied Logistic Regression. New York: John Wiley & Sons; 1989:271-274.
• [14]Rivera E: Targeted filgrastim support in patients with early-stage breast carcinoma. Cancer 2003, in press.